279 related articles for article (PubMed ID: 38364218)
1. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
3. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO
Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
7. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
8. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
Valverde-Monge M; Sánchez-Carrasco P; Betancor D; Barroso B; Rodrigo-Muñoz JM; Mahillo-Fernández I; Arismendi E; Bobolea I; Cárdaba B; Cruz MJ; Del Pozo V; Domínguez-Ortega J; González-Barcala FJ; Olaguibel JM; Luna-Porta JA; Martínez-Rivera C; Mullol J; Muñoz X; Peleteiro-Pedraza L; Picado Valles C; Plaza V; Quirce S; Rial MJ; Soto-Retes L; Valero A; Sastre J
Arch Bronconeumol; 2024 Jan; 60(1):23-32. PubMed ID: 38042707
[TBL] [Abstract][Full Text] [Related]
10. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
12. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
13. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
[TBL] [Abstract][Full Text] [Related]
14. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
15. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
16. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
[TBL] [Abstract][Full Text] [Related]
17. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.
Thomas D; McDonald VM; Stevens S; Harvey ES; Baraket M; Bardin P; Bowden JJ; Bowler S; Chien J; Chung LP; Gillman A; Hew M; Hodge S; James A; Jenkins C; Katelaris CH; Katsoulotos GP; Langton D; Lee J; Marks G; Peters M; Radhakrishna N; Reynolds PN; Rimmer J; Sivakumaran P; Upham JW; Wark P; Yang IA; Gibson PG
Allergy; 2024 Feb; 79(2):384-392. PubMed ID: 37632144
[TBL] [Abstract][Full Text] [Related]
18. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
20. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]